Skip to main content
Contact Us
Subscribe
E-Edition
65°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
114.55
-3.31 (-2.81%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
45
46
Next >
GILEAD SCIENCES INC (NASDAQ:GILD): A Prime Value Investing Candidate with Strong Fundamentals
September 13, 2025
Gilead Sciences (GILD) is a strong value investing candidate, trading at a significant discount with high profitability, solid financial health, and positive growth prospects.
Via
Chartmill
SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?
September 11, 2025
Via
Stocktwits
Tariffs Cast a Long Shadow: Consumer Prices Soar Across Essential Goods
September 10, 2025
American households are bracing for a significant financial hit as a wave of tariff-induced inflation sweeps across critical consumer goods and services. From the family car to essential baby products,...
Via
MarketMinute
Topics
Economy
Government
World Trade
Why Is Novo Nordisk’s Stock Rising Premarket Today?
September 10, 2025
Via
Stocktwits
Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued
September 09, 2025
Via
Stocktwits
CVS Health Reportedly Keeps Gilead’s New HIV Preventative Shot Off Its Plans, Faces $290M Medicare Fraud Ruling
August 20, 2025
Via
Stocktwits
Topics
Fraud
Cooling Wages Cast a Shadow: Economic Recovery at Risk as Consumer Spending Slows
September 10, 2025
The American economy is facing a new headwind as weakening wage growth begins to temper consumer spending, raising concerns about the pace and sustainability of the broader economic recovery. Recent...
Via
MarketMinute
Topics
Credit Cards
Economy
Supply Chain
Wolfspeed, Nvidia, Gilead, SLBM, Corning: What Sparked Heavy After-Hours Trading In These 5 Stocks?
September 09, 2025
On Monday, the tech-heavy Nasdaq Composite climbed to a new high despite the ongoing uncertainty regarding the state of the U.S. economy and the rate outlook.
Via
Stocktwits
Topics
Artificial Intelligence
Bankruptcy
Economy
Global Economic Slowdown and Escalating Tariffs: A Looming Threat to Market Growth
September 08, 2025
The global economy is currently grappling with a projected deceleration in GDP growth, a situation severely exacerbated by an unprecedented escalation of U.S. tariffs. These twin forces are creating a...
Via
MarketMinute
Topics
Economy
Supply Chain
World Trade
1 Healthcare Stock to Consider Right Now and 2 We Question
September 03, 2025
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID...
Via
StockStory
Topics
Stocks
Beating The September Curse–These 10 Stocks Shine While The S&P 500 Stumbles
September 02, 2025
September is historically the worst month for stocks, but these 10 S&P 500 companies have consistently delivered gains.
Via
Benzinga
Topics
Stocks
Veeva Makes A Bearish Move On One Pockmark In Its Quarterly Report
August 27, 2025
The company beat second-quarter expectations, with the exception of one key metric.
Via
Investor's Business Daily
Eli Lilly Scores Another Weight-Loss Win; Viking, Novo Stocks Slump
August 26, 2025
Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful test.
Via
Investor's Business Daily
Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win
August 26, 2025
The drug is soon to launch in Europe with a new name and a big potential market.
Via
Investor's Business Daily
Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences
August 25, 2025
While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an opportunity.
Via
Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
August 22, 2025
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 22, 2025
Via
Benzinga
Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy.
August 22, 2025
The tariffs will impact products imported from Europe, the Trump administration said late Thursday.
Via
Investor's Business Daily
Topics
ETFs
Government
Intellectual Property
Market Monitor News August 22 BMO - Coty Crumbles, Powell Looms: Wall Street Cautious Amid Mixed Signals
August 22, 2025
Markets dipped Thursday as Coty issued a dismal forecast, Gilead faced headwinds with its new HIV drug, and investors turned cautious ahead of Fed Chair Powell’s Jackson Hole speech. Solid PMI data...
Via
Chartmill
Topics
Economy
Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy
August 21, 2025
Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.
Via
Benzinga
Why Gilead Sciences (GILD) Shares Are Sliding Today
August 21, 2025
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to...
Via
StockStory
Topics
Earnings
These S&P500 stocks are gapping in today's session
August 21, 2025
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via
Chartmill
Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug
August 21, 2025
Insurance coverage is key for any new drug. But it's looking tenuous for Gilead Sciences' newest HIV prevention drug.
Via
Investor's Business Daily
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
August 21, 2025
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.
Via
Benzinga
Walgreens Grows Specialty Pharmacy Network To Meet Rising Demand For Complex Therapies
August 19, 2025
Walgreens boosts specialty drug network to 265 therapies, reinforcing its independent market position.
Via
Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) Presents a Compelling Case for Value Investors
August 19, 2025
Gilead Sciences (GILD) appears undervalued with strong profitability, a solid dividend, and moderate growth, offering a compelling case for value investors.
Via
Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
August 18, 2025
Via
Benzinga
Xilio Revenue Jumps 246 Percent in Q2
August 14, 2025
Via
The Motley Fool
Topics
Intellectual Property
Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions
August 14, 2025
Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and the launch of Yeztugo, its twice-yearly injectable for HIV prevention....
Via
StockStory
Topics
Earnings
Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks
August 13, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.
Via
StockStory
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
45
46
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.